India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India-focused Independent Equity Research Analyst

Experienced (7 years +) in Sector-Specific Deep Dives and Comprehensive Company Research.

With a sharp focus on the Indian market, I specialize in providing in-depth analysis and insights to investors. Whether it's dissecting various sectors to identify emerging trends or conducting thorough fundamental research on individual companies, I'm dedicated to uncovering valuable opportunities and delivering actionable intelligence.

Passionate about navigating the nuances of the Indian equity landscape, I thrive on deciphering complex market dynamics and distilling them into clear, concise insights. 

While covering a sector or company-specific research, I cover the following :
1. Brief about company/sector
2.  Overall Industry landscape - History, Present and Future trends
3. Thesis and Anti-Thesis
4. Valuations
5. Financial & Forensic Analysis
6. Management Review
7. Key Monitorable Events
8. Guidance and Future Way Ahead

India Equity Analyst - Fundamental & Thematic

Jana Small Finance Bank: Q1 FY27 Signals a Clear Turnaround

Indo-MIM IPO: From MIM Leadership to a Diversified Precision Manufacturing Platform

Eternal: Blinkit Profitability Driving a Strong Quarter!

Grasim Doubles Down on Renewables with ₹17,200 Crore Sprng Energy Deal

RateGain Travel Technologies: The $1 Billion Ambition by One of the Largest SaaS Providers

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

<ul>
<li>Fermenta Biotech, a global Vitamin D3 and speciality-ingredients manufacturer, delivered 26% underlying revenue growth, 44% EBITDA growth, INR 62 crore free cash flow, FSSAI approval and INR 110 crore expansion.</li>
<li>Plant-Source VITADEE Green, calcifediol and enzyme capacity can diversify a business still dominated by Vitamin D3, improve product differentiation and support repeatable specialty-ingredient growth.</li>
<li>Constructive but proof-dependent: order conversion, Dahej utilisation, normalized margins, working-capital discipline, leverage and Green Chemistry scale-up must demonstrate that the INR 110 crore expansion earns attractive returns.</li>
</ul>


Fermenta Biotech, a global Vitamin D3 and speciality-ingredients manufacturer, delivered 26% underlying revenue growth, 44% EBITDA growth, INR 62 crore free cash flow, FSSAI approval and INR 110 crore expansion.
Plant-Source VITADEE Green, calcifediol and enzyme capacity can diversify a business still dominated by Vitamin D3, improve product differentiation and support repeatable specialty-ingredient growth.
Constructive but proof-dependent: order conversion, Dahej utilisation, normalized margins, working-capital discipline, leverage and Green Chemistry scale-up must demonstrate that the INR 110 crore expansion earns attractive returns.


Fermenta Biotech: Specialty Nutrition and Green Chemistry Play